LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at Leerink Partnrs lifted their FY2028 earnings estimates for shares of LENZ Therapeutics in a note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn $2.00 per share for the year, up from their prior forecast of ($2.00). The consensus estimate for LENZ Therapeutics' current full-year earnings is ($3.15) per share.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.09.
Other analysts have also issued research reports about the stock. Raymond James initiated coverage on shares of LENZ Therapeutics in a research note on Friday, September 27th. They issued an "outperform" rating and a $37.00 target price for the company. William Blair raised shares of LENZ Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. Piper Sandler reiterated an "overweight" rating and issued a $36.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, August 15th. Finally, HC Wainwright began coverage on LENZ Therapeutics in a research note on Monday, August 12th. They issued a "buy" rating and a $38.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, LENZ Therapeutics presently has an average rating of "Buy" and a consensus target price of $35.40.
Read Our Latest Stock Analysis on LENZ Therapeutics
LENZ Therapeutics Trading Up 6.3 %
LENZ Therapeutics stock traded up $1.67 during trading on Friday, hitting $27.99. 103,771 shares of the company were exchanged, compared to its average volume of 132,569. The business's 50 day moving average is $23.13 and its 200 day moving average is $20.25. LENZ Therapeutics has a 52 week low of $14.07 and a 52 week high of $29.82.
Institutional Investors Weigh In On LENZ Therapeutics
A number of hedge funds have recently modified their holdings of the stock. RA Capital Management L.P. bought a new position in LENZ Therapeutics during the first quarter valued at $93,313,000. Vanguard Group Inc. purchased a new stake in LENZ Therapeutics in the 1st quarter worth about $4,621,000. Jennison Associates LLC bought a new stake in LENZ Therapeutics in the 1st quarter valued at about $3,009,000. Ikarian Capital LLC purchased a new stake in LENZ Therapeutics during the first quarter valued at about $1,898,000. Finally, Wealth Enhancement Advisory Services LLC bought a new position in LENZ Therapeutics during the second quarter worth about $1,437,000. Institutional investors own 54.32% of the company's stock.
About LENZ Therapeutics
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
See Also
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
